Who is sponsoring NCT03123406?

NCT03123406 is sponsored by Kyowa Kirin China Pharmaceutical Co., Ltd..

What drugs are being tested in NCT03123406?

Interventions in NCT03123406: Cinacalcet HCl.

What condition does NCT03123406 study?

NCT03123406 studies Hyperparathyroidism; Secondary, Renal.

Is NCT03123406 still recruiting?

NCT03123406 is currently completed. Last updated 29 April 2024.

Last reviewed 2024-04-29 · How we verify

NCT03123406: ACTIVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

Completed Phase 4 Last updated 29 April 2024

What this trial tests

Phase 4 trial testing Cinacalcet HCl in Hyperparathyroidism; Secondary, Renal in 750 participants. Completed in 6 September 2019.

Timeline

19 April 2017

Primary endpoint
20 April 2019

6 September 2019

Quick facts

Lead sponsor	Kyowa Kirin China Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	750
Start date	19 April 2017
Primary completion	20 April 2019
Estimated completion	6 September 2019
Sites	1 location across China

Drugs / interventions tested

Cinacalcet HCl — full drug profile →

Conditions studied

Hyperparathyroidism; Secondary, Renal — all drugs for Hyperparathyroidism; Secondary, Renal →

Sponsor

Kyowa Kirin China Pharmaceutical Co., Ltd.

Who can join

Adults 18 to 75, any sex, with Hyperparathyroidism; Secondary, Renal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2. To explore the impact of Cinacalcet HCL using on the combined use of drugs; 3. To explore the difference of patients who continued or discontinued Cinacalcet HCL in real-world period from 33rd to 52nd week.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cinacalcet HCl

Trials testing the same drug.

NCT02138838 — Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Dis · Phase 3 · terminated

Other Kyowa Kirin China Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06285370 — A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Pre · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03123406 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin China Pharmaceutical Co., Ltd.
Last refreshed: 29 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03123406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing